 Connection
Rohit Katial to Disease Progression
This is a "connection" page, showing publications Rohit Katial has written about Disease Progression.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.396 |
|
|
|
-
Menzies-Gow A, Hoyte FL, Price DB, Cohen D, Barker P, Kreindler J, Jison M, Brooks CL, Papeleu P, Katial R. A Response to: Letter to the Editor Regarding "Clinical Remission in Severe Asthma: A Pooled Post Hoc Analysis of the Patient Journey with Benralizumab". Adv Ther. 2022 08; 39(8):3862-3865.
Score: 0.125
-
Menzies-Gow A, Hoyte FL, Price DB, Cohen D, Barker P, Kreindler J, Jison M, Brooks CL, Papeleu P, Katial R. Clinical Remission in Severe Asthma: A Pooled Post Hoc Analysis of the Patient Journey with Benralizumab. Adv Ther. 2022 05; 39(5):2065-2084.
Score: 0.123
-
Dunn NM, Katial RK. Chronic Rhinosinusitis and Aspirin-Exacerbated Respiratory Disease. Immunol Allergy Clin North Am. 2016 08; 36(3):503-14.
Score: 0.083
-
Bleecker ER, Meyers DA, Billheimer D, Li H, Newbold P, Kwiatek J, Hirsch I, Katial R, Li X. Clinical Implications of Longitudinal Blood Eosinophil Counts in Patients With Severe Asthma. J Allergy Clin Immunol Pract. 2023 06; 11(6):1805-1813.
Score: 0.033
-
Chung Y, Katial R, Mu F, Cook EE, Young J, Yang D, Betts KA, Carstens DD. Real-world effectiveness of benralizumab: Results from the ZEPHYR 1 Study. Ann Allergy Asthma Immunol. 2022 06; 128(6):669-676.e6.
Score: 0.031
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|